Nabil Wasif1,2, Yu-Hui Chang3,4, Barbara A Pockaj5, Richard J Gray5, Amit Mathur6,4, David Etzioni7,4. 1. Division of Surgical Oncology, Department of Surgery, Mayo Clinic Arizona, Phoenix, USA. wasif.nabil@mayo.edu. 2. Surgical Outcomes Division, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic Arizona, Phoenix, USA. wasif.nabil@mayo.edu. 3. Department of Biostatistics, Mayo Clinic Arizona, Phoenix, AZ, USA. 4. Surgical Outcomes Division, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic Arizona, Phoenix, USA. 5. Division of Surgical Oncology, Department of Surgery, Mayo Clinic Arizona, Phoenix, USA. 6. Division of Transplant Surgery, Department of Surgery, Mayo Clinic Arizona, Phoenix, USA. 7. Division of Colorectal Surgery, Department of Surgery, Mayo Clinic Arizona, Phoenix, USA.
Abstract
BACKGROUND: The influence of distance traveled for treatment on short- and long-term cancer outcomes is unclear. METHODS: Patients with colon, esophageal, liver, and pancreas cancer from 2003 to 2006 were identified from the National Cancer Data Base (NCDB). Distance traveled for surgical treatment was estimated using zip code centroids. Propensity scores were generated for probability of traveling farther for treatment. Mixed effects logistic regression for 90-day mortality and Cox regression for 5-year mortality were compared between patients treated regionally and those traveling from farther away. RESULTS: The mean distance traveled for all patients for surgical resection was 30.0 ± 227 miles, with a median distance of 7.5 (interquartile range 14.4) miles. Patients who were aged ≥80 years, on Medicaid, or African American were less likely to be in the fourth quartile of distance (Q4) traveled for surgery. Patients who were in Q4 had a lower risk-adjusted 90-day mortality compared to Q1 for colon [odds ratio (OR) 0.89, 95 % confidence interval (CI) 0.82-0.96], liver (OR 0.49, 95 % CI 0.3-0.78), and pancreatic (OR 0.74, 95 % CI 0.56-0.98) cancer. Similarly, patients in Q4 for all tumor types had a lower risk-adjusted 5-year mortality compared to patients in Q1; colon (hazard ratio (HR) 0.96, 95 % CI 0.93-0.99), esophagus (HR 0.84, 95 % CI 0.75-0.94), liver (HR 0.75, 95 % CI 0.62-0.89), and pancreas (HR 0.87, 95 % CI 0.80-0.95). CONCLUSIONS: Greater travel distance for surgical resection of gastrointestinal cancers is associated with lower 90-day and 5-year mortality outcomes. This distance bias has implications for regionalization and reporting of cancer outcomes.
BACKGROUND: The influence of distance traveled for treatment on short- and long-term cancer outcomes is unclear. METHODS:Patients with colon, esophageal, liver, and pancreas cancer from 2003 to 2006 were identified from the National Cancer Data Base (NCDB). Distance traveled for surgical treatment was estimated using zip code centroids. Propensity scores were generated for probability of traveling farther for treatment. Mixed effects logistic regression for 90-day mortality and Cox regression for 5-year mortality were compared between patients treated regionally and those traveling from farther away. RESULTS: The mean distance traveled for all patients for surgical resection was 30.0 ± 227 miles, with a median distance of 7.5 (interquartile range 14.4) miles. Patients who were aged ≥80 years, on Medicaid, or African American were less likely to be in the fourth quartile of distance (Q4) traveled for surgery. Patients who were in Q4 had a lower risk-adjusted 90-day mortality compared to Q1 for colon [odds ratio (OR) 0.89, 95 % confidence interval (CI) 0.82-0.96], liver (OR 0.49, 95 % CI 0.3-0.78), and pancreatic (OR 0.74, 95 % CI 0.56-0.98) cancer. Similarly, patients in Q4 for all tumor types had a lower risk-adjusted 5-year mortality compared to patients in Q1; colon (hazard ratio (HR) 0.96, 95 % CI 0.93-0.99), esophagus (HR 0.84, 95 % CI 0.75-0.94), liver (HR 0.75, 95 % CI 0.62-0.89), and pancreas (HR 0.87, 95 % CI 0.80-0.95). CONCLUSIONS: Greater travel distance for surgical resection of gastrointestinal cancers is associated with lower 90-day and 5-year mortality outcomes. This distance bias has implications for regionalization and reporting of cancer outcomes.
Authors: Geoffrey M Kozak; Jeffrey D Epstein; Sandeep P Deshmukh; Benjamin B Scott; Scott W Keith; Harish Lavu; Charles J Yeo; Jordan M Winter Journal: J Gastrointest Surg Date: 2017-11-14 Impact factor: 3.452
Authors: Manila Jindal; Chaoyi Zheng; Humair S Quadri; Chukwuemeka U Ihemelandu; Young K Hong; Andrew K Smith; Vikas Dudeja; Nawar M Shara; Lynt B Johnson; Waddah B Al-Refaie Journal: J Am Coll Surg Date: 2017-04-14 Impact factor: 6.113
Authors: Adrian Diaz; Daniel Chavarin; Anghela Z Paredes; Diamantis I Tsilimigras; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2020-07-22 Impact factor: 5.344
Authors: Sean C O'Connor; Harveshp Mogal; Gregory Russell; Cecilia Ethun; Ryan C Fields; Linda Jin; Ioannis Hatzaras; Gerardo Vitiello; Kamran Idrees; Chelsea A Isom; Robert Martin; Charles Scoggins; Timothy M Pawlik; Carl Schmidt; George Poultsides; Thuy B Tran; Sharon Weber; Ahmed Salem; Shishir Maithel; Perry Shen Journal: J Gastrointest Surg Date: 2017-10-04 Impact factor: 3.452
Authors: Evan M Graboyes; Mark A Ellis; Hong Li; John M Kaczmar; Anand K Sharma; Eric J Lentsch; Terry A Day; Chanita Hughes Halbert Journal: Cancer Date: 2018-06-22 Impact factor: 6.860
Authors: Jeffrey E Johnson; Paula D Strassle; Guilherme C de Oliveira; Chris B Agala; Philip Spanheimer; Kristalyn Gallagher; David Ollila; Hyman Muss; Stephanie Downs-Canner Journal: Breast Cancer Res Treat Date: 2021-06-26 Impact factor: 4.624